U.S. pharma huge copyright scrapped two experimental weight loss pills last calendar year—a once-daily capsule, lotiglipron, resulting from elevated liver enzymes along with a twice-everyday tablet, danuglipron, as a result of potent Unintended effects—but CEO Albert Bourla has explained the company is decided to “Perform and get” from the